Histological Trends and the Index Lesion in Localized Prostate Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/9781444346893.CH3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy

  2011cited by this paper
• Tumor focality in prostate cancer: implications for focal therapy

  2011cited by this paper
• Pathologic basis of focal therapy for early-stage prostate cancer

  2009cited by this paper
• The index lesion and the origin of prostate cancer.

  2009cited by this paper
• Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology

  2009cited by this paper
• Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy

  2009cited by this paper
• Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer

  2009cited by this paper
• Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

  2008cited by this paper
• Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.

  2008cited by this paper
• Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer.

  2008cited by this paper
• Pathologic stage T2a and T2b prostate cancer in the recent prostate‐specific antigen era: Implications for unilateral ablative therapy

  2008cited by this paper
• Will focal therapy become a standard of care for men with localized prostate cancer?

  2007cited by this paper
• Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer

  2007cited by this paper
• Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study

  2006cited by this paper
• Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens

  2005cited by this paper
• Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.

  2005cited by this paper
• Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate

  2004cited by this paper
• Is tumor volume an independent prognostic factor in clinically localized prostate cancer?

  2004cited by this paper
• Characteristics of prostate cancers detected at low PSA levels

  2004cited by this paper
• Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients

  2003cited by this paper
• Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.

  2003cited by this paper
• Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens.

  2002cited by this paper
• Prostate cryoablation: a scientific rationale for future modifications.

  2002cited by this paper
• Molecular analysis of multifocal prostate cancer lesions

  1999cited by this paper
• Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer

  1998cited by this paper
• Genetic basis and clonal evolution of human prostate cancer.

  1996cited by this paper
• Original Articles: Prostate Cancer: Pathological Features of Hereditary Prostate Cancer

  1995cited by this paper
• Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration.

  1994cited by this paper
• Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors

  1992cited by this paper

• Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study

  2017cites this paper